Exome Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Exome Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.99M	Sell	88,177 -21,887	-20%	-$1.65M	4.31%	5
2026 Q1	$8.26M	Sell	110,064 -6,451	-6%	-$509K	4.27%	4
2025 Q4	$9.22M	Sell	116,515 -14,501	-11%	-$1.09M	4.41%	4
2025 Q3	$8.57M	Buy	131,016 +9,900	+8%	+$483K	5.19%	1
2025 Q2	$4.79M	Sell	121,116 -14,500	-11%	-$475K	3.56%	5
2025 Q1	$4.09M	Buy	135,616 +74,249	+121%	+$2.43M	3.64%	7
2024 Q4	$2.15M	Buy	+61,367	New	+$2.29M	1.61%	27

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Exome Asset Management's IONS Position: Q2 2026 in Review

Exome Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 20% in Q2 2026, selling an estimated $1.65M and leaving 88,177 shares worth $6.99M. The position accounts for 4.31% of the portfolio, ranked #5.

Exome Asset Management first reported a position in IONS in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.22M in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Exome Asset Management held 88,177 shares of Ionis Pharmaceuticals worth $6.99M as of Q2 2026.
Exome Asset Management sold 21,887 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
Ionis Pharmaceuticals made up 4.31% of Exome Asset Management's portfolio in Q2 2026, its #5 holding.
Exome Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Exome Asset Management's Ionis Pharmaceuticals position peaked at $9.22M in Q4 2025.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.